Telomir Pharmaceuticals (NASDAQ: TELO) announced the closing of its acquisition of TELI Pharmaceuticals, Inc., a move that establishes the company as the sole global rights holder of Telomir-1 (Telomir-Zn) and eliminates prior geographic fragmentation of the asset. The transaction, which was approved by shareholders in March, includes $1.0 million in funding at closing and up to an additional $4.0 million in milestone-based contributions tied to clinical development progress.
The acquisition strengthens Telomir's position as it advances Telomir-Zn toward the clinic following a recent Investigational New Drug (IND) submission for the treatment of advanced and metastatic triple-negative breast cancer. The company plans to initiate a Phase 1/2 trial upon regulatory clearance while retaining flexibility for potential global partnerships. This development is significant because it consolidates the intellectual property and development rights under one entity, potentially accelerating the drug's path to market and broadening its therapeutic applications.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Its lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The acquisition of TELI Pharmaceuticals ensures that all future development and commercialization efforts will be unified, avoiding the complexities and inefficiencies of fragmented ownership.
For investors and industry observers, this move signals Telomir's commitment to advancing its pipeline and maximizing the value of its lead asset. The additional milestone-based funding provides a financial runway to support clinical trials, while the flexibility to pursue global partnerships could open avenues for co-development or licensing deals. The news is particularly relevant for those tracking developments in oncology and aging-related therapeutics, as Telomir-1 targets mechanisms that are central to both fields.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics. More information is available in the company's newsroom at https://ibn.fm/TELO. The full press release can be viewed at https://ibn.fm/DcY4o.
